Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Asset Writedowns and Impairment (2019 - 2021)

AVITA Medical's Asset Writedowns and Impairment history spans 3 years, with the latest figure at $23000.0 for Q4 2021.

  • For Q4 2021, Asset Writedowns and Impairment rose 560.0% year-over-year to $23000.0; the TTM value through Dec 2023 reached $42000.0, changed N/A, while the annual FY2023 figure was $4000.0, N/A changed from the prior year.
  • Asset Writedowns and Impairment reached $23000.0 in Q4 2021 per RCEL's latest filing, up from $19000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $23000.0 in Q4 2021 to a low of -$77000.0 in Q3 2020.
  • Average Asset Writedowns and Impairment over 3 years is -$3500.0, with a median of $9500.0 recorded in 2019.
  • Peak YoY movement for Asset Writedowns and Impairment: crashed 1062.5% in 2020, then soared 560.0% in 2021.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $11000.0 in 2019, then crashed by 145.45% to -$5000.0 in 2020, then skyrocketed by 560.0% to $23000.0 in 2021.
  • Per Business Quant, the three most recent readings for RCEL's Asset Writedowns and Impairment are $23000.0 (Q4 2021), $19000.0 (Q3 2021), and -$5000.0 (Q4 2020).